Scientific deep-dive

GLP-1s and Inflammatory Bowel Disease

The pivotal trials excluded people with IBD, so the evidence is retrospective: 13 of 14 studies. It has not linked GLP-1s to more flares, and that null result deserves careful reading.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

If you have Crohn’s disease or ulcerative colitis, the obvious worry about a drug that deliberately slows the gut is whether it will stir up your gut. The pivotal trials cannot tell you, because people with IBD were excluded from them.[1] What exists instead is a body of retrospective evidence assembled afterwards. The useful questions are what it says and how much weight it can carry.

What the review found

A 2026 systematic review searched the literature to September 2025 and found 14 studies of GLP-1 drugs in adults with IBD. Ten reported significant reductions in body weight, BMI or percentage weight loss. Four showed improvements in metabolic markers, including lower HbA1c and more favorable lipids.[1]

On the main worry, across multiple datasets GLP-1 use was not associated with increased IBD exacerbations.[1] That is the headline, and it is reassuring as far as it goes.

Thirteen of those fourteen studies were retrospective cohorts. There is no randomized trial here. That matters more than usual for a reassuring null result, because of who gets prescribed: a gastroenterologist is less likely to start a weight-loss drug in someone whose disease is flaring. Healthier patients receiving the drug would produce exactly this finding even if the drug did nothing. The result is consistent with safety; it does not establish it.

Why the question is reasonable in the first place

These drugs delay gastric emptying and slow transit, and their commonest adverse effects (nausea, diarrhea, abdominal pain, constipation) are the same symptoms that IBD produces and that patients and clinicians use to judge whether disease is active.

That overlap is a practical problem separate from any question of harm. New abdominal pain and altered stool on a GLP-1 could be the drug settling in or a flare beginning, and telling those apart is difficult. Our side-effect timeline covers what the ordinary course looks like, which is the baseline you would be comparing against.

Nausea, diarrhea, abdominal pain and constipation are both the drug’s commonest adverse effects and the symptoms used to judge whether IBD is active.

The case for treating it anyway

The review opens by noting that obesity and metabolic disease are increasingly common in people with IBD, and they influence disease activity and how well treatment works.[1] This is not a population where excess weight is cosmetic.

So the choice is between two managed risks, in a person who often has fewer good options than average. That is a decision for a gastroenterologist who knows your disease history, not one to make from a website, and it is the kind of case where the specialist’s judgment is doing most of the work.

What would change the picture

  • A randomized trial that includes people with IBD. The single thing that would convert this from consistent-with-safety to established.
  • Prospective data with disease activity scored properly, rather than exacerbations inferred from records where a flare and a side effect can look identical.
  • Separate answers for Crohn’s and colitis. They behave differently, and the current evidence largely does not distinguish them.
  • Data on people with surgical history or strictures, where slowed transit is a more specific concern than it is in inflammatory disease generally.

Frequently Asked Questions

People with IBD do take them, and the available evidence has not linked it to more flares. But people with IBD were excluded from the pivotal trials, so that evidence is retrospective. In a 2026 systematic review, 13 of 14 studies were retrospective cohorts. It is a decision for your gastroenterologist.
Across multiple datasets in a 2026 systematic review, GLP-1 use was not associated with increased IBD exacerbations. That is reassuring, with the caveat that clinicians are less likely to prescribe these drugs to someone whose disease is active, which would produce the same finding even if the drug had an effect.
With difficulty. Nausea, abdominal pain, diarrhea and constipation are both the drug's common adverse effects and the symptoms used to judge disease activity. That overlap is a reason to involve your IBD team when starting, rather than to interpret new symptoms yourself.
Roughly, as far as anyone can tell. The few studies that compared people with and without IBD found small differences in both directions. Ten of the fourteen studies reported significant reductions in weight or BMI, and four showed metabolic improvements including lower HbA1c. The evidence base is small and retrospective, so the effect size is less certain than in the general population.

References

  1. 1.Maracle B, Quan S, Hamilton P, et al. Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP-1 Receptor Agonists in Inflammatory Bowel Disease Alimentary Pharmacology & Therapeutics. 2026. PMID: 41319219.

Which GLP-1 Has the Worst Side Effects?

A network meta-analysis of 33,354 people ranks the drugs symptom by symptom. Orforglipron, the oral pill, tops the nausea ranking, ahead of every injection.

5 min read

Is Tirzepatide Anti-Inflammatory, or Just Slimming?

A meta-analysis pooling six studies shows hsCRP and IL-6 falling on tirzepatide. But CRP rises with body fat, because fat tissue releases the signals that drive the liver to make it, and it falls with weight loss of any kind, and the analysis compares people who lost weight against people who did not.

5 min read

MOTS-c: What the Evidence Shows, and What FDA Found

MOTS-c slowed weight gain and improved insulin sensitivity in mice. No published trial has given it to people, and there is no established human dose. The 503A bulks list leaves it out; under an interim HHS policy dated October 2026, HHS does not intend to take enforcement action against 503A compounding under strict conditions.

11 min read

Zepbound for Sleep Apnea: What SURMOUNT-OSA Actually Found

On December 20, 2024 the FDA cleared Zepbound for obstructive sleep apnea, and no other drug of any kind holds that indication. The trials cut breathing interruptions by 25 to 29 an hour, and left the average participant still inside the moderate band.

7 min read

Metformin and a GLP-1 Together: The Risk Is Not the One People Expect

The diabetes trials behind these drugs were largely run on people already taking metformin. Stomach side effects did not stack in the largest analysis, and low blood sugar comes from other drugs. The real overlap is dehydration.

8 min read

GLP-1 Drugs and Eating Disorders: Two Questions, One Studied

Five studies covering 182 people make up the whole meta-analytic evidence base in binge eating disorder. What happens when these drugs reach someone with a restrictive eating disorder has never been studied at all.

6 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.0

YourEra

Semaglutide at $99/month, well below the typical price

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

7.3

Found

People who want clinician visits billed to commercial insurance, with compounded medication in the plan price

From $149/mo + membership

Get started →
Read full review →

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →